Merus NV (MRUS): Net earnings per share growth forecast for next year

Corporate company logo of merus.nl (MRUS)

Merus N.V. (MRUS) develops multispecific antibodies via the Biclonics system to combat cancer. Financial stability is supported by cash reserves and partner payments. Changes in analyst EPS growth estimates on the GURU.Markets chart reflect a trend where the 7.10 level captures the latest values. A broad spectrum of early-stage programs diversifies risk, shielding the company from potential failures in individual studies.

Merus NV (MRUS): Expected earnings per share growth for next year from 07/04/2022 to 01/10/2026

merus.nl - analytical breakdowns and key metrics (MRUS)

- share price and consensus valuation forecast:
Stock Price Merus Corp|MRUS - Average Forecast Price
- stock exchange capitalization data:
Market Value Merus|MRUS - Business Value
- company book value details:
Net Assets per Single Share Merus|MRUS - Company Net Assets|Market Capitalization to Book Value Ratio merus.nl|MRUS - Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Merus N.V.|MRUS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Merus|MRUS - Company Aggregate Debts|Debt to Book Capitalization Ratio Merus|MRUS - Long-Term Debt Volume|Company Current Liabilities Merus|Quick Liquidity merus.nl
- net income and valuation ratios data:
MRUS - Company Profit|Future Profit Merus N.V.|MRUS - Business Payback Period|Projected Price to Earnings Merus N.V.|MRUS - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Merus|MRUS - Operating income before deduction of amortization|Earnings per share for the last twelve months Merus|MRUS - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months merus.nl|MRUS - Earnings per share increase in current year|Expected earnings per share growth for next year Merus N.V.
Basic company analysis:MRUS, Merus Corp
Core merchandise of Merus NV

The biotech sector's high sensitivity to external shocks is mitigated in Merus N.V. (MRUS) through the strategic outsourcing of antibody production, which minimizes operational risks and accelerates clinical trials. By analyzing the consensus for next year's earnings per share, an investor can view the aggregated net income forecast, allowing them to filter out market noise and assess the asset's fundamental value without overpaying.

Competitor analysis

IMMP (Immutep Limited ADR) - Earnings growth forecast for next year|Expected net earnings per share growth next year Anixa Bio ANIX|Net earnings per share growth forecast for next year Atossa Therapeutics (ATOS)|contexttherapeutics.com - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year Mersana Therapeutics, Inc. MRSN|BCTX - Expected earnings per share growth for next year|ESSA Pharma Inc - Earnings growth forecast for next year|Expected net earnings per share growth next year QT Imaging, Inc.